Thursday, 12 January 2017

Global Gastrointestinal Therapeutics Market is Expected to Grow at a CAGR of 6.5% During the Period 2016-2020


Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract.

They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota.

Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn's disease, ulcerative colitis, and peptic ulcers.

The report analysts forecast the global gastrointestinal therapeutics market to grow at a CAGR of 6.5% during the period 2016-2020.

Covered in this report:

The report covers the present scenario and the growth prospects of the global gastrointestinal therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS).

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
Gastrointestinal Therapeutics market has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Johnson & Johnson
  • Takeda
  • Allergan
  • UCB
Other prominent vendors 
  • 4SC
  • Ajinomoto Pharmaceuticals
  • Alfa Wassermann
  • Alizyme
  • Amgen
  • Anterogen
  • Ardelyx
  • Arena Pharmaceuticals
  • Astellas
  • AstraZeneca
  • Astellas Pharma
  • Avaxia Biologics
  • Biogen Idec
  • BioLineRx
  • Celgene
  • ChemoCentryx
  • Cosmo Pharmaceuticals
  • Drais Pharmaceuticals
  • Eisai
  • Eli Lilly
  • Enlivex Therapeutics
  • F. Hoffmann-La Roche
  • Ferring Pharmaceuticals
  • FF Pharma
  • Galapagos
  • Gilead Sciences
  • GlaxoSmithKline
  • Hutchison Medi Pharma
  • Immune Pharmaceuticals
  • InDex Pharmaceuticals
  • Ironwood Pharmaceuticals
  • Kaken Pharmaceutical
  • Kang Stem Biotech
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • Lipid Therapeutics
  • Meda
  • Merck
  • Mesoblast
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Morphotek
  • Neovacs
  • Nestle
  • Norgine
  • Novartis
  • Ono Pharmaceutical
  • Pfizer
  • Procter & Gamble
  • Qu Biologics
  • Receptos
  • RedHill Biopharma
  • Salix Pharmaceuticals
  • Shield Therapeutics
  • Sterna Biologicals
  • Synergy Pharmaceuticals
  • Synthetic Biologics
  • TiGenix
  • Tillotts Pharma
  • TopiVert
  • TSD Japan
  • Zeria Pharmaceutical
Market driver
  • Tentative approval of late stage molecules
  • For a full, detailed list, view our report
Market challenge
  • Discontinuation of drugs under development and from the market
  • For a full, detailed list, view our report
Market trend
  • Emergence of biosimilars
  • For a full, detailed list, view our report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

No comments:

Post a Comment